Swing et al:

The thing that catches my eye is the last para:

"On the other hand, if consummation of a partnership looks unlikely at this point in time and MannKind needs to launch Afrezza solo, how much filling equipment could be installed with these funds"

50M = 6 new lines if we take the suggest price tag of 8M per...

This would give them 200% additional output (if I am not mistaken they already have 3 lines) or the capability of sustaining 1.5M patients annually or about 75% of the current facilicites max output capacity.

OOG